Viking Therapeutics, Inc. (VKTX) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$26.91

From 52W high−35.25%

Volume1.64M

Market cap$3.48B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$26.91

From 52W high

−35.25%

Volume

1.64M

Market cap

$3.48B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.4x

P/E (TTM)

—

RSI (14)

47.5

MomentumView details →

1D Return

+4.57%

YTD Return

−23.37%

SummaryUpdated Sep 1, 2026

Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in San Diego, California. The company went public in 2015 and focuses on developing novel therapies for metabolic and endocrine disorders. Viking has emerged as a significant player in the obesity and metabolic disease treatment space, with multiple drug candidates in various stages of clinical development targeting conditions such as obesity, non-alcoholic steatohepatitis (NASH), and rare metabolic disorders.

Ask drillr about Viking Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−4.4x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

5.9x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−106.56%

ROA (TTM)

−64.19%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+4.57%

YTD Return

−23.37%

1Y Return

−26.08%

RSI (14)

47.5

vs 50D SMA

−10.38%

vs 200D SMA

−16.55%

Capital & dividendView details →

Debt/Equity

0.43x

Current Ratio

7.27x

Quick Ratio

7.27x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.55

EPS Surprise

−46.23%

Beats (12Q)

3/12

Next Q EPS Est

−$1.38

Avg Surprise (4Q)

−31.59%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−627.20M

Op. CF (TTM)

−462.63M

Next earningsFeb 10, 2027 →

Latest newsMore news →

Viking Therapeutics, Inc. reported a wider third-quarter loss as rising clinical expenses weighed on results.6d ago

Viking Therapeutics, Inc. reported financial results for the third quarter and nine months ended September 30, 2026, and reported a quarter-end cash position of $960 million.7d ago

Similar companies

Dyne Therapeutics, Inc.DYN Amylyx Pharmaceuticals, Inc.AMLX Tarsus Pharmaceuticals, Inc.TARS Denali Therapeutics Inc.DNLI Celcuity Inc.CELC Tennor Therap-b06872.HK Find similar companies →

Latest newsMore news →

Viking Therapeutics, Inc. reported a wider third-quarter loss as rising clinical expenses weighed on results.6d ago Viking Therapeutics, Inc. reported financial results for the third quarter and nine months ended September 30, 2026, and reported a quarter-end cash position of $960 million.7d ago Viking Therapeutics, Inc. announced positive top-line results from its VK2735 maintenance dosing study and initiated Part 2 of the study.7d ago